Givertz, M. M., Mann, D. L., Lee, K. L., Ibarra, J. C., Velazquez, E. J., Hernandez, A. F., … Braunwald, E. (2013). Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail, 6(4), 862–868. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000394

Givertz, Michael M., Douglas L. Mann, Kerry L. Lee, Jenny C. Ibarra, Eric J. Velazquez, Adrian F. Hernandez, Alice M. Mascette, and Eugene Braunwald. “Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.” Circ Heart Fail 6, no. 4 (July 2013): 862–68. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000394.

Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, et al. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail. 2013 Jul;6(4):862–8.

Givertz, Michael M., et al. “Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.” Circ Heart Fail, vol. 6, no. 4, July 2013, pp. 862–68. Pubmed, doi:10.1161/CIRCHEARTFAILURE.113.000394.

Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail. 2013 Jul;6(4):862–868.